Use of topical cyclosporin A in a primary Sjogren's syndrome mouse model

Kazuo Tsubota, I. Saito, N. Ishimaru, Y. Hayashi

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

PURPOSE. A new animal model, the NFS/sld mutant mouse, was used for primary Sjogren's syndrome to investigate the efficacy of topical and systemic cyclosporin A (CyA) in preventing inflammation of the exocrine glands. METHODS. Cyclosporin A was applied topically (0.01% and 0.1%, three times a day) or administered orally (10 mg/kg and 100 mg/kg, once a day) to mice from 6 to 16 weeks of age, after which the mice were killed. RESULTS. Topical CyA reduced lacrimal gland and submandibular gland inflammation without causing pathologic changes in other organs. Flow cytometry showed that CD44 expression of CD4 T cells from the submandibular lymph nodes was downregulated, whereas that of Mel14+ was upregulated. Using a reverse transcription-polymerase chain reaction assay, we determined that topical CyA significantly decreased the expression of mRNA of IL-2 and T-cell receptor- constant β-chain. CONCLUSIONS. Topical CyA may be clinically useful in reducing the lymphocyte infiltration of lacrimal glands associated with Sjogren's syndrome.

Original languageEnglish
Pages (from-to)1551-1559
Number of pages9
JournalInvestigative Ophthalmology and Visual Science
Volume39
Issue number9
Publication statusPublished - 1998
Externally publishedYes

Fingerprint

Sjogren's Syndrome
Cyclosporine
Lacrimal Apparatus
Exocrine Glands
Inflammation
Submandibular Gland
T-Cell Antigen Receptor
Reverse Transcription
Interleukin-2
Flow Cytometry
Down-Regulation
Animal Models
Lymph Nodes
Lymphocytes
T-Lymphocytes
Polymerase Chain Reaction
Messenger RNA

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Use of topical cyclosporin A in a primary Sjogren's syndrome mouse model. / Tsubota, Kazuo; Saito, I.; Ishimaru, N.; Hayashi, Y.

In: Investigative Ophthalmology and Visual Science, Vol. 39, No. 9, 1998, p. 1551-1559.

Research output: Contribution to journalArticle

Tsubota, Kazuo ; Saito, I. ; Ishimaru, N. ; Hayashi, Y. / Use of topical cyclosporin A in a primary Sjogren's syndrome mouse model. In: Investigative Ophthalmology and Visual Science. 1998 ; Vol. 39, No. 9. pp. 1551-1559.
@article{f86dce3212c549a8851345908c812da2,
title = "Use of topical cyclosporin A in a primary Sjogren's syndrome mouse model",
abstract = "PURPOSE. A new animal model, the NFS/sld mutant mouse, was used for primary Sjogren's syndrome to investigate the efficacy of topical and systemic cyclosporin A (CyA) in preventing inflammation of the exocrine glands. METHODS. Cyclosporin A was applied topically (0.01{\%} and 0.1{\%}, three times a day) or administered orally (10 mg/kg and 100 mg/kg, once a day) to mice from 6 to 16 weeks of age, after which the mice were killed. RESULTS. Topical CyA reduced lacrimal gland and submandibular gland inflammation without causing pathologic changes in other organs. Flow cytometry showed that CD44 expression of CD4 T cells from the submandibular lymph nodes was downregulated, whereas that of Mel14+ was upregulated. Using a reverse transcription-polymerase chain reaction assay, we determined that topical CyA significantly decreased the expression of mRNA of IL-2 and T-cell receptor- constant β-chain. CONCLUSIONS. Topical CyA may be clinically useful in reducing the lymphocyte infiltration of lacrimal glands associated with Sjogren's syndrome.",
author = "Kazuo Tsubota and I. Saito and N. Ishimaru and Y. Hayashi",
year = "1998",
language = "English",
volume = "39",
pages = "1551--1559",
journal = "Investigative Ophthalmology and Visual Science",
issn = "0146-0404",
publisher = "Association for Research in Vision and Ophthalmology Inc.",
number = "9",

}

TY - JOUR

T1 - Use of topical cyclosporin A in a primary Sjogren's syndrome mouse model

AU - Tsubota, Kazuo

AU - Saito, I.

AU - Ishimaru, N.

AU - Hayashi, Y.

PY - 1998

Y1 - 1998

N2 - PURPOSE. A new animal model, the NFS/sld mutant mouse, was used for primary Sjogren's syndrome to investigate the efficacy of topical and systemic cyclosporin A (CyA) in preventing inflammation of the exocrine glands. METHODS. Cyclosporin A was applied topically (0.01% and 0.1%, three times a day) or administered orally (10 mg/kg and 100 mg/kg, once a day) to mice from 6 to 16 weeks of age, after which the mice were killed. RESULTS. Topical CyA reduced lacrimal gland and submandibular gland inflammation without causing pathologic changes in other organs. Flow cytometry showed that CD44 expression of CD4 T cells from the submandibular lymph nodes was downregulated, whereas that of Mel14+ was upregulated. Using a reverse transcription-polymerase chain reaction assay, we determined that topical CyA significantly decreased the expression of mRNA of IL-2 and T-cell receptor- constant β-chain. CONCLUSIONS. Topical CyA may be clinically useful in reducing the lymphocyte infiltration of lacrimal glands associated with Sjogren's syndrome.

AB - PURPOSE. A new animal model, the NFS/sld mutant mouse, was used for primary Sjogren's syndrome to investigate the efficacy of topical and systemic cyclosporin A (CyA) in preventing inflammation of the exocrine glands. METHODS. Cyclosporin A was applied topically (0.01% and 0.1%, three times a day) or administered orally (10 mg/kg and 100 mg/kg, once a day) to mice from 6 to 16 weeks of age, after which the mice were killed. RESULTS. Topical CyA reduced lacrimal gland and submandibular gland inflammation without causing pathologic changes in other organs. Flow cytometry showed that CD44 expression of CD4 T cells from the submandibular lymph nodes was downregulated, whereas that of Mel14+ was upregulated. Using a reverse transcription-polymerase chain reaction assay, we determined that topical CyA significantly decreased the expression of mRNA of IL-2 and T-cell receptor- constant β-chain. CONCLUSIONS. Topical CyA may be clinically useful in reducing the lymphocyte infiltration of lacrimal glands associated with Sjogren's syndrome.

UR - http://www.scopus.com/inward/record.url?scp=0031877239&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031877239&partnerID=8YFLogxK

M3 - Article

C2 - 9699544

AN - SCOPUS:0031877239

VL - 39

SP - 1551

EP - 1559

JO - Investigative Ophthalmology and Visual Science

JF - Investigative Ophthalmology and Visual Science

SN - 0146-0404

IS - 9

ER -